Efficacy Of Psilocybin

Creso’s acquisition target Halucenex to extend clinical trials beyond veterans

Finfeed Archived Jun 08, 2021

Creso Pharma's (ASX: CPH) targeted acquisition company Halucenex intends to expand its phase II clinical trial to include non-veterans.